Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

2.45
+0.03001.24%
Post-market: 2.480.0330+1.35%18:32 EDT
Volume:4.39M
Turnover:10.74M
Market Cap:730.07M
PE:-4.43
High:2.49
Open:2.31
Low:2.31
Close:2.42
Loading ...

AbCellera Biologics Is Maintained at Overweight by Keybanc

Dow Jones
·
16 Apr

AbCellera price target raised to $5 from $4 at KeyBanc

TIPRANKS
·
16 Apr

KeyBanc Remains a Buy on AbCellera Biologics (ABCL)

TIPRANKS
·
16 Apr

AbCellera to Participate at Upcoming Investor Conferences in May and June

Business Wire
·
09 Apr

Press Release: AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Dow Jones
·
04 Apr

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Business Wire
·
26 Mar

AbCellera Biologics (ABCL) Gets a Buy from Truist Financial

TIPRANKS
·
03 Mar

AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
01 Mar

AbCellera Biologics’ Earnings Call: Transition Amid Challenges

TIPRANKS
·
01 Mar

Stock Track | AbCellera Stock Plummets 16.78% in Pre-Market After Wider 2024 Loss Despite Pipeline Progress

Stock Track
·
28 Feb

Stock Track | AbCellera Stock Plunges 5.8% Pre-Market on Wider 2024 Loss Despite Pipeline Progress

Stock Track
·
28 Feb

AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ...

GuruFocus.com
·
28 Feb

AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
28 Feb

Abcellera Biologics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)

TIPRANKS
·
28 Feb

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
28 Feb

BRIEF-AbCellera Biologics Files For Mixed Shelf, Size Not Disclosed - SEC Filing

Reuters
·
28 Feb

AbCellera files automatic mixed securities shelf

TIPRANKS
·
28 Feb

Abcellera Biologics Inc Files for Mixed Shelf ; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
28 Feb

AbCellera Biologics Q4 GAAP EPS $(0.12) Beats $(0.15) Estimate, Sales $5.10M Miss $7.58M Estimate

Benzinga
·
28 Feb